274 related articles for article (PubMed ID: 17023173)
1. Decitabine--bedside to bench.
Oki Y; Aoki E; Issa JP
Crit Rev Oncol Hematol; 2007 Feb; 61(2):140-52. PubMed ID: 17023173
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation.
Samlowski WE; Leachman SA; Wade M; Cassidy P; Porter-Gill P; Busby L; Wheeler R; Boucher K; Fitzpatrick F; Jones DA; Karpf AR
J Clin Oncol; 2005 Jun; 23(17):3897-905. PubMed ID: 15753459
[TBL] [Abstract][Full Text] [Related]
3. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies.
Hackanson B; Robbel C; Wijermans P; Lübbert M
Ann Hematol; 2005 Dec; 84 Suppl 1():32-8. PubMed ID: 16292549
[TBL] [Abstract][Full Text] [Related]
4. DNA methylation and gene silencing in cancer.
Baylin SB
Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S4-11. PubMed ID: 16341240
[TBL] [Abstract][Full Text] [Related]
5. 5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation.
Scott SA; Dong WF; Ichinohasama R; Hirsch C; Sheridan D; Sanche SE; Geyer CR; Decoteau JF
Leuk Res; 2006 Jan; 30(1):69-76. PubMed ID: 16043219
[TBL] [Abstract][Full Text] [Related]
6. Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors.
Cowan LA; Talwar S; Yang AS
Epigenomics; 2010 Feb; 2(1):71-86. PubMed ID: 22122748
[TBL] [Abstract][Full Text] [Related]
7. Demethylation of DNA by decitabine in cancer chemotherapy.
Brown R; Plumb JA
Expert Rev Anticancer Ther; 2004 Aug; 4(4):501-10. PubMed ID: 15270655
[TBL] [Abstract][Full Text] [Related]
8. Decitabine, differently from DNMT1 silencing, exerts its antiproliferative activity through p21 upregulation in malignant pleural mesothelioma (MPM) cells.
Amatori S; Papalini F; Lazzarini R; Donati B; Bagaloni I; Rippo MR; Procopio A; Pelicci PG; Catalano A; Fanelli M
Lung Cancer; 2009 Nov; 66(2):184-90. PubMed ID: 19233506
[TBL] [Abstract][Full Text] [Related]
9. Decitabine: 2'-deoxy-5-azacytidine, Aza dC, DAC, dezocitidine, NSC 127716.
Drugs R D; 2003; 4(3):179-84. PubMed ID: 12757405
[TBL] [Abstract][Full Text] [Related]
10. Clinical development of decitabine as a prototype for an epigenetic drug program.
Rosenfeld CS
Semin Oncol; 2005 Oct; 32(5):465-72. PubMed ID: 16210087
[TBL] [Abstract][Full Text] [Related]
11. Transformation-dependent silencing of tumor-selective apoptosis-inducing TRAIL by DNA hypermethylation is antagonized by decitabine.
Lund P; Kotova I; Kedinger V; Khanwalkar H; Voltz E; Hahn WC; Gronemeyer H
Mol Cancer Ther; 2011 Sep; 10(9):1611-23. PubMed ID: 21697397
[TBL] [Abstract][Full Text] [Related]
12. Oral decitabine reactivates expression of the methylated gamma-globin gene in Papio anubis.
Lavelle D; Chin J; Vaitkus K; Redkar S; Phiasivongsa P; Tang C; Will R; Hankewych M; Roxas B; Singh M; Saunthararajah Y; Desimone J
Am J Hematol; 2007 Nov; 82(11):981-5. PubMed ID: 17696208
[TBL] [Abstract][Full Text] [Related]
13. 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy.
Christman JK
Oncogene; 2002 Aug; 21(35):5483-95. PubMed ID: 12154409
[TBL] [Abstract][Full Text] [Related]
14. DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia.
Yang AS; Doshi KD; Choi SW; Mason JB; Mannari RK; Gharybian V; Luna R; Rashid A; Shen L; Estecio MR; Kantarjian HM; Garcia-Manero G; Issa JP
Cancer Res; 2006 May; 66(10):5495-503. PubMed ID: 16707479
[TBL] [Abstract][Full Text] [Related]
15. Decitabine.
Daskalakis M; Blagitko-Dorfs N; Hackanson B
Recent Results Cancer Res; 2010; 184():131-57. PubMed ID: 20072836
[TBL] [Abstract][Full Text] [Related]
16. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias.
Leone G; Teofili L; Voso MT; Lübbert M
Haematologica; 2002 Dec; 87(12):1324-41. PubMed ID: 12495905
[TBL] [Abstract][Full Text] [Related]
17. Decitabine: development of a DNA methyltransferase inhibitor for hematological malignancies.
Lyons J; Bayar E; Fine G; McCullar M; Rolens R; Rubinfeld J; Rosenfeld C
Curr Opin Investig Drugs; 2003 Dec; 4(12):1442-50. PubMed ID: 14763130
[TBL] [Abstract][Full Text] [Related]
18. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine.
Stresemann C; Lyko F
Int J Cancer; 2008 Jul; 123(1):8-13. PubMed ID: 18425818
[TBL] [Abstract][Full Text] [Related]
19. p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia.
Link PA; Baer MR; James SR; Jones DA; Karpf AR
Cancer Res; 2008 Nov; 68(22):9358-66. PubMed ID: 19010910
[TBL] [Abstract][Full Text] [Related]
20. Hypomethylating agents for urologic cancers.
Alva AS; Hahn NM; Aparicio AM; Singal R; Yellapragada S; Sonpavde G
Future Oncol; 2011 Mar; 7(3):447-63. PubMed ID: 21417907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
